Human amnion-derived mesenchymal stem cells transplantation improveshematopoietic function of myelosuppression mice

doi:10.3969/j.issn.2095-4344.2013.23.010

Abstract

Abstract:

BACKGROUND: High-dose chemotherapy often results in severe bone marrow damage. Beside medicines, stem cells transplantation has also been as a strategy for the treatment of bone marrow damage.
OBJECTIVE: To investigate the effects of human amnion-derived mesenchymal stem cells transplantation on the hematopoietic function of myelosuppression mice induced by cisplatin.
METHODS: Human amnion-derived mesenchymal stem cells were cultured in vitro. The female Imprinting Control Region mice were divided into three groups. Excepted for the mice in the blank group, the mice in the other groups were intraperitoneal injected with cisplatin to make the myelosuppression Imprinting Control Region mice, then the 3.0×105/g human amnion-derived mesenchymal stem cells were injected into the mice in the human amnion-derived mesenchymal stem cells transplantation group through the caudal vein, and PBS solution in the same dose was injected in the mice of blank group and model group.
RESULTS AND CONCLUSION: On day 7, the body weight of Imprinting Control Region mice was reduced after administrated with cisplatin for 7 days, there was no significant difference between model group and human amnion-derived mesenchymal stem cells transplantation group. The number of white blood cells, lymphocytes,mononuclear cells, red blood cells, hemoglobin, hematocrit and platelet of peripheral blood in the model group were significantly lower than those in the blank group (P < 0.05), then the indexes above began to recover on day 21 after cisplatin treatment. The recovery of the indexes above of the peripheral blood in the human amnion-derived mesenchymal stem cells transplantation group was 7 days earlier than that in the model group, and the indexes above were recovered to normal level at 21 days; compared with blank group, the number of white blood cells and platelet in the human amnion-derived mesenchymal stem cells transplantation group was transiently increased at 1-2 days before transplantation and 2 days after transplantation. At 24 days after transplantation, the number of bone marrow karyocytes in human amnion-derived mesenchymal stem cells transplantation group was significantly higher than that in the model group (P < 0.05). Bone marrow histopathological testing results showed that the mice femur bone marrow organizational structure in the human amnion-derived mesenchymal stem cells transplantation group was significantly improved. Compared with blank group, the number of bone marrow nucleated cells, especially megakaryocytes, was higher in human amnion-derived mesenchymal stem cells transplantation group, and at 2 weeks after human amnion-derived mesenchymal stem cells transplantation, many mouse anti-human nuclei monoclonal antibody-FITC positive cells were colonized in myeloid tissue. These results showed that human amnion-derived mesenchymal stem cells transplantation can remarkably ameliorate hematopoietic function in cisplatin induced myelosuppression mice.

Key words: stem cells, stem cell transplantation, human amniotic mesenchymal stem cells, cisplatin, bone marrow suppression, hematopoietic function, mice, white blood cells, red blood cells, lymphocytes, mononuclear cells, hemoglobin, hematocrit, platelet, National Natural Science Foundation of China, stem cell photographs-containing paper

CLC Number:

R318

Yao Guan-ping, Yu Li-mei, Fan Zhen-hai, Fang Ning, Ren Fei, Luo Jiao, Zhang Xiao-yu, Wang Yu-ying, Liu Jin-wei. Human amnion-derived mesenchymal stem cells transplantation improveshematopoietic function of myelosuppression mice[J]. Chinese Journal of Tissue Engineering Research, 2013, 17(23): 4248-4255.

Figures/Tables 7

References

[1]Thuss Patience PC, Kretzschmar A, Reichardt P. Docetaxel in the treatment of gastric cancer. Future Oncol.2006;2(5): 603-620.

[2]Janeway KA, Grier HE. Sequelae of osteosarcoma medical therapy: a review of rare acute toxicities and late effects. Lancet Oncol.2010; 11(7):670-678.

[3]Wang SB,Guo KY,Hu DM,et al.Zhongguo Zuzhi Gongcheng Yanjiu yu Linchuang Kangfu.2008;12(25):4811-4813.王三斌,郭坤元,胡灯明,等.以SEAM预处理方案行自体外周血干细胞移植治疗非何杰金淋巴瘤[J].中国组织工程研究与临床康复, 2008,12(25):4811-4813.

[4]Vranovsky A,Ladicka M,Lakota J.Autologous stem cell transplantion in first-line treatment of high-risk aggressive non-Hodgkin's lymphoma.Neoplasma.2008;55(2):107-112.

[5]Hamlin PA,Zelenetz AD,Kewalramani T, et al. Age adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. Blood.2003; 02(6): 1989-1996.

[6]Espigado I,Ros E,Marn-Niebla A,et al.High rate of longterm survival for high-risk lymphoma patients treated with hematopoietic stem cell transplantation as consolidation or salvage therapy. Transplant Proc. 2008;40(9):3104-3105.

[7]Li SQ,Chen DD,Gao LZ.Zhongguo Linchuang Yaolixue yu Zhiliaoxue.2008;13(2):201-207.李胜前,陈丁丁,高利忠.河鲀Ⅰ型胶原蛋白提取物防治环磷酰胺、顺铂或阿糖胞苷诱发小鼠骨髓抑制的研究[J].中国临床药理学与治疗学.2008;13(2):201-207.

[8]In 't Anker PS, Scherjon SA, Kleijburg-van der Keur C, et al.Isolation of mesenchymal stem cells of fetal or maternal origin from human placenta. Stem Cells.2004;22(7): 1338-1345.

[9]Parolini O,Alviano F,Bagnara GP,etal.Concise review:isolation and characterization of cells from human term placenta:outcome of the first international Workshop on Placenta Derived Stem Cells.Stem Cells. Stem Cells.2008; 26(2):300-311.

[10]Li GX,Yang B,Guan FX,etal.Zhengzhou Daxue Xuebao: Yixueban. 2006;41(2): 244 -247.李国喜,杨波,关方霞,等.人羊膜来源间质干细胞的分离、培养及鉴定[J].郑州大学学报(医学版).2006;41(2):244-247.

[11]Sakuragawa N,Enosawa S,Ishii T,et al.Human amniotic epithelial cells are promising transgene carriers for allogeneic cell transplantation into liver.J Hum Genet.2000;45:171-176.

[12]Reyes M, Dudek A, Jahagirdar B, et al. Origin of endothelial progenitors in human postnatal bone marrow. J Clin Invest 2002;109 (3):337-346.

[13]The Ministry of Science and Technology of the People’s Republic of China. Guidance Suggestions for the Care and Use of Laboratory Animals. 2006-09-30.中华人民共和国科学技术部. 关于善待实验动物的指导性意见. 2006-09-30.

[14]Fang N,Zhang L,Song XJ,et al.Zunyi Yixueyuan Xuebao. 2009; 32(3):234-236.方宁,张路,宋秀军,等.人羊膜间充质干细胞的分离、培养及鉴定[J].遵义医学院学报,2009,32(3):234-236.

[15]Chen Q.Beijing:People’s Medical Publishing House. 2006: 1167.陈奇.中药药理研究方法学[M].北京:人民卫生出版社,2006: 1167.

[16]Carey PJ.Drug-induced myelosuppression:diagnosis and management. Drug Saf.2003;26:691-706．

[17]Chen Y,Shao JZ,Xiang LX et al.Mesenchymal stem cells: a promising candidate in regenerative medicine. Int J Biochem Cell Biol.2008;40:815.

[18]Niwa H,Masui S,Chambers I,et al. Phenotypic complementation establishes requirements for specific POU domain and generic transactivation function of Oct-3/4 in embryonic stem cells.Mol Cell Biol.2002;22(5):1526-1536.

[19]Strem BM,Hicok KC,Zhu M,et al.Multipotential different tiation of adipose tissue-derived stem cells.Keio J Med.2005; 54: 132-141

[20]Moon J H,Lee JR,Jee BC,et al.Successful vitrification of human amnion- derived mesenchymal stem cells.Hum Reprod.2008;23(8):1760 -1770.

[21]Wolbank S,Peterbauer A,Fahrner M,et al.Dose-dependent immunomodulatory effect of human stem cells from amniotic membrane:A comparison with human mesenchymal stem cells from adiposetissue.Tissue Eng.2007;13(6):1173- 1183.

[22]Kobayashi M,Yakuwa T,Sasaki K,et a1.Multilineage potential of side population cells from human amnion mesenchymal layer. Cell Transplantation, 2008;(17):291-301

[23]Kita K,Gauglitz GG,Phan TT,et al.Isolation and characterization of mesenchymal stem cells from the sub-amniotic human umbilical cord lining membrane.Stem Cells Dev.2010;19(4):491-502.